Q-omics provides the consensus-scored MROH2A profile across patient tissues and cancer cell-line models. MROH2A expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, MROH2A is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, MROH2A RNA expression shows 10,725 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, THCA, and GBM as cancer lineages where MROH2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MROH2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MROH2A survival associations across molecular data types. MROH2A RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MROH2A RNA expression–survival associations across cancer types. High MROH2A expression shows unfavorable associations in KIRP, MESO, KICH, LGG and ESCA, but favorable associations in THYM. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for MROH2A RNA expression.
This table summarizes MROH2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MROH2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MROH2A shows lower tumor expression in THCA, CHOL and LIHC and higher tumor expression in KIRC, UCEC and HNSC. The THCA box plot shows higher MROH2A RNA expression in normal versus tumor tissue (log2 FC = −1.247, t-test p < 0.001).
This table shows molecular features associated with MROH2A in patient tissues and cancer cell lines. In patient samples, MROH2A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MROH2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BONE and OESOPHAGUS.
